Mucosal vaccine development for botulinum intoxication

References

• Bienenstock J, McDermott M, Befus D, O’Neill M. A common mucosal immunologic system involving the bronchus, breast and bowel. Adv. Exp. Med. Biol.107, 53–59 (1978).
   PubMedGoogle Scholar
• Boyaka PB, Marinaro M, Fujihashi K, McGhee JR. Host defenses at mucosal surfaces. In: Clinical Immunology. Rich RR, Fleisher TA, Shearer WT, Kotzin BL, Schroedoer JHW (Eds). Mosby International Ltd, London, UK, 20.21–20.18 (2001).
   Google Scholar
• Mestecky J, Blumberg RS, Kiyono H, McGhee JR. The mucosal immune system. In: Fundamental Immunology. Paul WE (Ed.). Lippincott Williams & Wilkins, PA, USA, 965–1020 (2003).
   Google Scholar
• Fujihashi K, Boyaka PN, McGhee JR. Mucosal immune responses. In: Topley and Wilson’s Microbiology and Microbial Infections. Kaufmann SHE, Sreward M (Eds). Edward Arnold Limited, London, UK, 519–554 (2005).
   Google Scholar
• Bernstein JM. Mucosal immunology of the upper respiratory tract. Respiration59, 3–13 (1992).
   PubMedGoogle Scholar
• Kuper CF, Koornstra PJ, Hameleers DM et al. The role of nasopharyngeal lymphoid tissue. Immunol. Today13, 219–224 (1992).
   PubMedGoogle Scholar
• Hagiwara Y, McGhee JR, Fujihashi K et al. Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue. J. Immunol.170, 1754–1762 (2003).
   PubMedGoogle Scholar
• Yamamoto S, Kiyono H, Yamamoto M et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl Acad. Sci. USA94, 5267–5272 (1997).
   PubMed Web of Science ®Google Scholar
• Namikoshi J, Otake S, Maeba S et al. Specific antibodies induced by nasally administered 40-kDa outer membrane protein of Porphyromonas gingivalis inhibits coaggregation activity of P. gingivalis. Vaccine22, 250–256 (2003).
   PubMed Web of Science ®Google Scholar
• Kweon MN, Yamamoto M, Watanabe F et al. A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies. J. Infect. Dis.186, 1261–1269 (2002).
   PubMed Web of Science ®Google Scholar
• Hirabayashi Y, Kurata H, Funato H et al. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine8, 243–248 (1990).
   PubMed Web of Science ®Google Scholar
• Tamura SI, Kurata T. Intranasal immunization with influenza vaccine. In: Mucosal Vaccines. Kiyono H, Ogra PL, McGhee JR (Eds). Academic Press, Inc., CA, USA, 425–436 (1996).
   Google Scholar
• Tamura S, Ito Y, Asanuma H et al. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J. Immunol.149, 981–988 (1992).
   PubMed Web of Science ®Google Scholar
• Hashigucci K, Ogawa H, Ishidate T et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine14, 113–119 (1996).
   PubMedGoogle Scholar
• van Ginkel FW, McGhee JR, Liu C et al. Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene. J. Immunol.159, 685–693 (1997).
   PubMed Web of Science ®Google Scholar
• van Ginkel FW, Liu C, Simecka JW et al. Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and β-galactosidase. Hum. Gene Ther.6, 895–903 (1995).
   PubMed Web of Science ®Google Scholar
• Sakaguchi G. Clostridium botulinum toxins. Pharmacol. Ther.19, 165–194 (1982).
   PubMed Web of Science ®Google Scholar
• Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu. Rev. Pharmacol. Toxicol.26, 427–453 (1986).
   PubMed Web of Science ®Google Scholar
• Simpson LL, Maksymowych AB, Kiyatkin N. Botulinum toxin as a carrier for oral vaccines. Cell. Mol. Life Sci.56, 47–61 (1999).
   PubMedGoogle Scholar
• Sugiyama H. Clostridium botulinum neurotoxin. Microbiol. Rev.44, 419–448 (1980).
   PubMedGoogle Scholar
• MacDonald KL, Cohen ML, Blake PA. The changing epidemiology of adult botulism in the United States. Am. J. Epidemiol.124, 794–799 (1986).
   PubMed Web of Science ®Google Scholar
• Bonventre PF. Absorption of botulinal toxin from the gastrointestinal tract. Rev. Infect. Dis.1, 663–667 (1979).
   PubMedGoogle Scholar
• DasGupta BR, Sugiyama H. A common subunit structure in Clostridium botulinum type A, B and E toxins. Biochem. Biophys. Res. Commun.48, 108–112 (1972).
   PubMedGoogle Scholar
• Inoue K, Fujinaga Y, Watanabe T et al. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect. Immun.64, 1589–1594 (1996).
   PubMed Web of Science ®Google Scholar
• Oguma K, Fujinaga Y, Inoue K. Structure and function of Clostridium botulinum toxins. Microbiol. Immunol.39, 161–168 (1995).
   PubMedGoogle Scholar
• Coleman IW. Studies on the oral toxicity of Clostridium botulinum toxin, type A. Can. J. Biochem. Physiol.32, 27–34 (1954).
   PubMedGoogle Scholar
• Dack G, Gibbard J. Permeability of the small intestine of rabbits and hogs to botulinum toxin. J. Infect. Dis.39, 181–185 (1926).
   Google Scholar
• Dack GM, Gibbard J. Studies on botulinum toxin in the alimentary tract of hogs rabbits, guinea pigs and mice. J. Infect. Dis.39, 173–180 (1926).
   Google Scholar
• Dack GM, Hoskins D. Absorption of botulinum toxin from the colon of Macaca mulatta. J. Infect. Dis.71, 2610–2613 (1942).
   Google Scholar
• Dack GM, Wood WL. Inpermeability of the small intestine of rabbits to botulinum toxin. J. Infect. Dis.40, 585–587 (1927).
   Google Scholar
• Halliwell G. The action of proteolytic enzymes on Clostridium botulinum type A toxin. Biochem. J.58, 4–8 (1954).
   PubMedGoogle Scholar
• Heckly RJ, Hildebrand GJ, Lamanna C. On the size of the toxic particle passing the intestinal barrier in botulism. J. Exp. Med.111, 745–759 (1960).
   PubMedGoogle Scholar
• Kalamanson GM, Bronfenbrenner J. Restortion of activity of neutralized biologic agents by removal of the antibody with papain. J. Immunol.47, 387–407 (1943).
   Google Scholar
• Lamanna C, Eklund HW, McElroy OE. Botulinum toxin (type A); including a study of shaking with chloroform as a step in the isolation procedure. J. Bacteriol.52, 1–13 (1946).
   Web of Science ®Google Scholar
• Littauer U. Observations on the type A toxin of Clostridium botulinum. Nature167, 994–995 (1951).
   PubMedGoogle Scholar
• May AJ, Whaler BC. The absorption of Clostridium botulinum type A toxin from the alimentary canal. Brit. J. Exp. Path.39, 307–316 (1958).
   PubMed Web of Science ®Google Scholar
• Ohishi I, Sugii S, Sakaguchi G. Oral toxicities of Clostridium botulinum toxins in response to molecular size. Infect. Immun.16, 107–109 (1977).
   PubMed Web of Science ®Google Scholar
• Sugii S, Ohishi I, Sakaguchi G. Correlation between oral toxicity and in vitro stability of Clostridium botulinum type A and B toxins of different molecular sizes. Infect. Immun.16, 910–914 (1977).
   PubMed Web of Science ®Google Scholar
• Sugii S, Ohishi I, Sakaguchi G. Intestinal absorption of botulinum toxins of different molecular sizes in rats. Infect. Immun.17, 491–496 (1977).
   PubMedGoogle Scholar
• Ohishi I, Sakaguchi G. Oral toxicities of Clostridium botulinum type C and D toxins of different molecular sizes. Infect. Immun.28, 303–309 (1980).
   PubMedGoogle Scholar
• Ohishi I. Oral toxicities of Clostridium botulinum type A and B toxins from different strains. Infect. Immun.43, 487–490 (1984).
   PubMedGoogle Scholar
• Maksymowych AB, Simpson LL. Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells. J. Biol. Chem.273, 21950–21957 (1998).
   PubMed Web of Science ®Google Scholar
• Maksymowych AB, Reinhard M, Malizio CJ et al. Pure botulinum neurotoxin is absorbed from the stomach and small intestine and produces peripheral neuromuscular blockade. Infect. Immun.67, 4708–4712 (1999).
   PubMed Web of Science ®Google Scholar
• Kozaki S, Kamata Y, Nagai T, Ogasawara J, Sakaguchi G. The use of monoclonal antibodies to analyze the structure of Clostridium botulinum type E derivative toxin. Infect. Immun.52, 786–791 (1986).
   PubMedGoogle Scholar
• Kozaki S, Miyazaki S, Sakaguchi G. Development of antitoxin with each of two complementary fragments of Clostridium botulinum type B derivative toxin. Infect. Immun.18, 761–766 (1977).
   PubMedGoogle Scholar
• Clayton MA, Clayton JM, Brown DR, Middlebrook JL. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect. Immun.63, 2738–2742 (1995).
   PubMed Web of Science ®Google Scholar
• Middlebrook JL. Protection strategies against botulinum toxin. Adv. Exp. Med. Biol.383, 93–98 (1995).
   PubMedGoogle Scholar
• Atassi MZ, Dolimbek BZ, Hayakari M et al. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855–1296 with antitoxin antibodies from three host species. J. Protein Chem.15, 691–700 (1996).
   PubMedGoogle Scholar
• Oshima M, Hayakari M, Middlebrook JL, Atassi MZ. Immune recognition of botulinum neurotoxin type A: regions recognized by T cells and antibodies against the protective H(C) fragment (residues 855–1296) of the toxin. Mol. Immunol.34, 1031–1040 (1997).
   PubMed Web of Science ®Google Scholar
• Oshima M, Middlebrook JL, Atassi MZ. Antibodies and T cells against synthetic peptides of the C-terminal domain (Hc) of botulinum neurotoxin type A and their cross-reaction with Hc. Immunol. Lett.60, 7–12 (1998).
   PubMed Web of Science ®Google Scholar
• Rosenberg JS, Middlebrook JL, Atassi MZ. Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Immunol. Invest.26, 491–504 (1997).
   PubMed Web of Science ®Google Scholar
• Bavari S, Pless DD, Torres ER, Lebeda FJ, Olson MA. Identifying the principal protective antigenic determinants of type A botulinum neurotoxin. Vaccine16, 1850–1856 (1998).
   PubMed Web of Science ®Google Scholar
• Quan CP, Berneman A, Pires R, Avrameas S, Bouvet JP. Natural polyreactive secretory immunoglobulin A autoantibodies as a possible barrier to infection in humans. Infect. Immun.65, 3997–4004 (1997).
   PubMed Web of Science ®Google Scholar
• Crottet P, Corthesy B. Secretory component delays the conversion of secretory IgA into antigen-binding competent F(ab')2: a possible implication for mucosal defense. J. Immunol.161, 5445–5453 (1998).
   PubMed Web of Science ®Google Scholar
• Russell MW, Kilian M, Lamm ME. Biological activities of IgA. In: Mucosal Immunology. Ogra PL, Mestecky J, Lamm ME et al. (Eds). Academic Press, CA, USA 225–240 (1998).
   Google Scholar
• Kroese FG, de Waard R, Bos NA. B-1 cells and their reactivity with the murine intestinal microflora. Semin. Immunol.8, 11–18 (1996).
   PubMedGoogle Scholar
• Shroff KE, Meslin K, Cebra JJ. Commensal enteric bacteria engender a self-limiting humoral mucosal immune response while permanently colonizing the gut. Infect. Immun.63, 3904–3913 (1995).
   PubMed Web of Science ®Google Scholar
• Rejnek JJ, Travnicek J, Kostka J. Study of the effect of antibodies in the intestinal tract of germ-free baby pigs. Folia. Microbiol.13, 36–42 (1968).
   Web of Science ®Google Scholar
• Kraehenbuhl J-P, Neutra MR. Monoclonal secretory IgA for protection of the intestinal mucosa against viral and bacterial pathogens. In: Handbook of Mucosal Immunology. Ogra PL, Mestecky J, Lamm ME et al. (Eds). Academic Press, CA, USA (1994).
   Google Scholar
• Renegar KB, Small JPA. Passive immunization: systemic and mucosal. In: Mucosal Immunology. Ogra PL, Mestecky J, Lamm ME et al. (Eds). Academic Press, CA, USA 729–738 (1998).
   Google Scholar
• Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedrud JG. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc. Natl Acad. Sci. USA89, 6901–6905 (1992).
   PubMed Web of Science ®Google Scholar
• Peppard JV, Russell MW. Phylogenetic development and comparative physiology of IgA. In: Mucosal Immunology. Ogra PL, Mestecky J, Lamm ME et al. (Eds). Academic Press, CA, USA 163–179 (1998).
   Google Scholar
• Byrne MP, Smith LA. Development of vaccines for prevention of botulism. Biochimie82, 955–966 (2000).
   PubMed Web of Science ®Google Scholar
• Arnon SS, Schechter R, Inglesby TV et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA285, 1059–1070 (2001).
   PubMed Web of Science ®Google Scholar
• Singh BR, DasGupta BR. Molecular differences between type A botulinum neurotoxin and its toxoid. Toxicon27, 403–410 (1989).
   PubMedGoogle Scholar
• Byrne MP, Smith TJ, Montgomery VA, Smith LA. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect. Immun.66, 4817–4822 (1998).
   PubMed Web of Science ®Google Scholar
• Crosby RM, Richardson KK, Craft TR et al. Molecular analysis of formaldehyde-induced mutations in human lymphoblasts and E. coli. Environ. Mol. Mutagen.12, 155–166 (1988).
   Google Scholar
• Hatheway CL. Toxoid of Clostridium botulinum type F: purification and immunogenicity studies. Appl. Environ. Microbiol.31, 234–242 (1976).
   PubMed Web of Science ®Google Scholar
• Wartew GA. The health hazards of formaldehyde. J. Appl. Toxicol.3, 121–126 (1983).
   PubMed Web of Science ®Google Scholar
• Dertzbaugh MT, West MW. Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum. Vaccine14, 1538–1544 (1996).
   PubMedGoogle Scholar
• Lee JS, Pushko P, Parker MD et al. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect. Immun.69, 5709–5715 (2001).
   PubMed Web of Science ®Google Scholar
• Bennett AM, Perkins SD, Holley JL. DNA vaccination protects against botulinum neurotoxin type F. Vaccine21, 3110–3117 (2003).
   PubMed Web of Science ®Google Scholar
• Gelzleichter TR, Myers MA, Menton RG et al. Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalation model. J. Appl. Toxicol.19(Suppl. 1), S35–S38 (1999).
   Google Scholar
• Benton KA, Misplon JA, Lo CY et al. Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or γ δ T cells. J. Immunol.166, 7437–7445 (2001).
   PubMed Web of Science ®Google Scholar
• Mbawuike IN, Pacheco S, Acuna CL et al. Mucosal immunity to influenza without IgA: an IgA knockout mouse model. J. Immunol.162, 2530–2537 (1999).
   PubMed Web of Science ®Google Scholar
• Asanuma H, Koide F, Suzuki Y et al. Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration. Vaccine13, 3–5 (1995).
   PubMedGoogle Scholar
• Kadowaki S, Chen Z, Asanuma H et al. Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation. Vaccine18, 2779–2788 (2000).
   PubMed Web of Science ®Google Scholar
• Tamura S, Funato H, Hirabayashi Y et al. Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza. Vaccine8, 479–485 (1990).
   PubMed Web of Science ®Google Scholar
• Asahi-Ozaki Y, Yoshikawa T, Iwakura Y et al. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J. Med. Virol.74, 328–335 (2004).
   PubMed Web of Science ®Google Scholar
• Taysse L, Daulon S, Calvet J et al. Induction of acute lung injury after intranasal administration of toxin botulinum a complex. Toxicol. Pathol.33, 336–342 (2005).
   PubMed Web of Science ®Google Scholar
• Arnon SS, Damus K, Thompson B, Midura TF, Chin J. Protective role of human milk against sudden death from infant botulism. J. Pediatr.100, 568–573 (1982).
   PubMedGoogle Scholar
• Kiyatkin N, Maksymowych AB, Simpson LL. Induction of an immune response by oral administration of recombinant botulinum toxin. Infect. Immun.65, 4586–4591 (1997).
   PubMedGoogle Scholar
• Foynes S, Holley JL, Garmory HS, Titball RW, Fairweather NF. Vaccination against type F botulinum toxin using attenuated Salmonella enterica var Typhimurium strains expressing the BoNT/F H(C) fragment. Vaccine21, 1052–1059 (2003).
   PubMedGoogle Scholar
• Atlas RM. Bioterriorism: from threat to reality. Annu. Rev. Microbiol.56, 167–185 (2002).
   PubMed Web of Science ®Google Scholar
• Franz DR, Jahrling PB, Friedlander AM et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA278, 399–411 (1997).
   PubMed Web of Science ®Google Scholar
• Simpson LL. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol.44, 167–193 (2004).
   PubMed Web of Science ®Google Scholar
• Mahmut N, Inoue K, Fujinaga Y et al. Mucosal immunisation with Clostridium botulinum type C 16 S toxoid and its non-toxic component. J. Med. Microbiol.51, 813–820 (2002).
   PubMedGoogle Scholar
• Kobayashi R, Kohda T, Kataoka K et al. A novel neurotoxoid vaccine prevents mucosal botulism. J. Immunol.174, 2190–2195 (2005).
   PubMedGoogle Scholar
• Park JB, Simpson LL. Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect. Immun.71, 1147–1154 (2003).
   PubMed Web of Science ®Google Scholar
• Nowakowski A, Wang C, Powers DB et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl Acad. Sci. USA99, 11346–11350 (2002).
   PubMed Web of Science ®Google Scholar
• Mikszta JA, Sullivan VJ, Dean C et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis.191, 278–288 (2005).
   PubMed Web of Science ®Google Scholar
• Peachman KK, Rao M, Alving CR et al. Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen. Infect. Immun.74, 794–797 (2006).
   PubMed Web of Science ®Google Scholar
• Maddaloni M, Staats HF, Mierzejewska D et al. Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A. J. Immunol.177, 5524–5532 (2006).
   PubMedGoogle Scholar
• van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol.165, 4778–4782 (2000).
   PubMed Web of Science ®Google Scholar
• Eriksson AM, Schon KM, Lycke NY. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J. Immunol.173, 3310–3319 (2004).
   PubMed Web of Science ®Google Scholar
• van Ginkel FW, Jackson RJ, Yoshino N et al. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect. Immun.73, 6892–6902 (2005).
   PubMed Web of Science ®Google Scholar
• Yoshino N, Lu FX, Fujihashi K et al. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates. J. Immunol.173, 6850–6857 (2004).
   PubMed Web of Science ®Google Scholar
• Kataoka K, McGhee JR, Kobayashi R et al. Nasal Flt3 ligand cDNA elicits CD11c+CD8+ dendritic cells for enhanced mucosal immunity. J. Immunol.172, 3612–3619 (2004).
   PubMed Web of Science ®Google Scholar
• Lee SE, Kim SY, Jeong BC et al. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect. Immun.74, 694–702 (2006).
   PubMed Web of Science ®Google Scholar
• Lillard JW Jr, Boyaka PN, Hedrick JA, Zlotnik A, McGhee JR. Lymphotactin acts as an innate mucosal adjuvant. J. Immunol.162, 1959–1965 (1999).
   PubMedGoogle Scholar
• Lillard JW Jr, Boyaka PN, Taub DD, McGhee JR. RANTES potentiates antigen-specific mucosal immune responses. J. Immunol.166, 162–169 (2001).
   PubMed Web of Science ®Google Scholar
• Marinaro M, Boyaka PN, Jackson RJ et al. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin. J. Immunol.162, 114–121 (1999).
   PubMed Web of Science ®Google Scholar
• Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine16, 1216–1224 (1998).
   PubMed Web of Science ®Google Scholar